Doctor Biographies
P. Peter Xaysanasy, DPM
Dr. Xaysanasy serves as the technology officer and sponsor for the ELG clinical trials study. He coordinates the reports generated by the clinical trials study to the FDA. The duties will include supervision of the trials for compliance, safety, certification of laboratory reports of ELG results for submission. In addition, reports will be sent to IRB Integreview for compliance.
Summary of Positions
- Founder, Executive Director ELG3 Corporation, Rochester, N.Y., 2016 - Present
- Chief Technology Officer, R&D Diabetes Mellitus
- President & CEO XP Technology, LLC 2014 - Present
- CEO Northwest Arkansas Podiatry Center, Inc., 2000 – 2012
- Organogenesis Inc. Clinical Consultant, Diabetes Mellitus Clinical Study panel, 2002-2003.
- Tyson Foods, Research and Development Chemist; 1990 – 1994
Expertise
Peter’s recent work is focused on optoelectronic engineering, especially as applied to medical devices. He has been studying and developing noninvasive techniques for use in Diabetes Mellitus for clinical applications. This includes the study of optical properties of gycosylated hemoglobin and hemoglobin variant, as well as hemolysate in vascular tissue.
In order to bring the ELG product to market, Peter and the ELG team have been conducting extensive pre-clinical laboratory studies. In particular, he has been testing correlation methods to the National Glycohemoglobin Standardization Procedure, and to the Federation of Clinical Chemistry in preparation for IRB review and the FDA clinical trial.
Peter has extensive experience in the experimental and theoretical optical spectroscopy of organic and inorganic physical chemistry. Related healthcare experiences in wound care, sport medicine and podiatric surgery, diabetes related wound care and limp preservation procedures.
Education
- Residency: Gouverneur Hospital, New York, NY. and Peninsula Hospital, Bayside, NY. May 1999-2000. Related coursework: Podiatric medicine and surgery.
- New York College of Podiatric Medicine, Manhattan, NY. May 1999.
- University of Arkansas, Fayetteville, Arkansas. B.S. 1991. Chemistry
- Doctorate in Podiatric Medicine 1999
- B.S. in Chemistry 1991
Related Education and Training
Clinical chemistry and hematology: Northwest Medical Center. Clinical chemistry and hemolysate morphology. Cross trained in virology, pathology, hematology, fluid collections and preservation techniques. June 1991.
Laboratory methods: University of Arkansas. Division of Continuing Education. Trained in analytical methods and standardization procedures. April 1995.
Member of The American Institute of Chemists.
Dr. Joe Philip Rouse, M.D.
Dr. Rouse serves as the medical director for the clinical trials study. His function will include identifying each subject’s medical profiles criteria as approved by the FDA. In addition, he will give medical examinations, monitor blood chemistry, vitals, and record laboratory results comparison to the ELG study. He will identify any possible risks associated with glucose fasting and oversee the overall care of the subject safety during the trials.
Summary of Positions
- Owner, Rouse Family Medical Clinic, Fayetteville, AR. 1991 – Present
- Solo Practitioner Family Practice, Fayetteville, AR. 1975 – 1991
- US Navy Retired, Captain (06) 2003
Expertise
In addition to being a long-time family practice specialist in Fayetteville, Arkansas, Dr. Rouse has 48 years of diverse experience including clinical laboratory study. He is also a current Trustee for a charity contributing to Indiana University School of Medicine’s micro vascular research.
Dr. Rouse has hospital privileges with Washington Regional Medical Center and Northwest Medical Center in Northwest Arkansas.
Education
Residency US Naval Hospital, Jacksonville, FL, 1970 – 1973
Internship US Naval Hospital, San Diego, CA, 1970 – 1971
University of Arkansas, Fayetteville
- Doctorate in Medicine 1970
- B.A. Medicine 1970
- B.S. Chemistry 1968